Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b

被引：29

作者：

Bramanti, P

Sessa, E

Rifici, C

D'Aleo, G

Floridia, D

Di Bella, P

Lublin, F

机构：

[1] Univ Messina, Ctr Studio & Trattamento Neurol Lungodegenti, I-98124 Messina, Italy

[2] Univ Messina, Cattedra Neurofisiopatol, I-98124 Messina, Italy

[3] Allegheny Univ Hlth Sci, Dept Neurol, Philadelphia, PA 19102 USA

来源：

NEUROLOGY | 1998年 / 51卷 / 06期

关键词：

D O I：

10.1212/WNL.51.6.1720

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Spasticity is a disabling symptom of MS that is enhanced during interferon beta-1b (IFN beta-1b) treatment. Nineteen patients with primary progressive MS were treated with IFN beta-1b; an additional 19 patients did not receive this treatment. Thirteen of the 19 patients treated with IFN beta-1b had increased spasticity requiring increased antispasticity drug administration. This observation suggests that further studies are needed before interferons can be so widely used in primary progressive MS patients.

引用

页码：1720 / 1723

页数：4

共 5 条

[1]

KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444

[2] Management of patients receiving interferon beta-1b for multiple sclerosis: Report of a consensus conference [J].